Myosana Therapeutics is developing a targeted non-viral gene delivery platform specifically for treating neuromuscular and cardiac genetic diseases, such as Duchenne muscular dystrophy. This technology aims to overcome the limitations of viral delivery methods, expanding treatment options for patients facing significant unmet needs in genetic disease therapy.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene therapy approaches for neuromuscular and cardiac diseases often rely on viral vectors, which can present limitations in terms of immunogenicity, payload size, and targeting specificity. These challenges restrict the range of treatable diseases and patient populations, leaving significant unmet needs in genetic disease therapy.
Solution
Myosana Therapeutics is developing a targeted non-viral gene delivery platform designed to overcome the limitations associated with viral-based gene therapies for neuromuscular and cardiac diseases. The platform aims to deliver therapeutic genes directly to muscle cells with improved precision and reduced off-target effects. By utilizing a non-viral approach, Myosana seeks to expand the applicability of gene therapy to a broader range of genetic muscle diseases, including Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (MTM), with the potential to improve patient outcomes and quality of life. The technology is designed to increase longevity for patients and their families.
Target Audience
The primary target audience includes patients with neuromuscular and cardiac genetic diseases, such as Duchenne muscular dystrophy and X-linked myotubular myopathy, as well as their families and the clinicians who treat them.
Features
- Targeted delivery of therapeutic genes to muscle cells
- Non-viral vector design to minimize immunogenicity
- Potential for larger genetic payloads compared to viral vectors
- Amenable to treatment of a broad range of neuromuscular disorders and cardiomyopathies